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Bacteria that simultaneously produce multiple extended-spectrum beta-lactamases are frequently isolated.
We report an Enterobacter cloacae isolate, ES24, producing four different beta-lactamases (AmpC type beta-
lactamase, TEM-1, SHV-7, and a novel extended-spectrum beta-lactamase, SHV-30). Direct sequencing of
blaSHV gene products gave a “double peak” at position 703, suggesting the presence of more than one allele.
Using fluorescence resonance energy transfer real-time PCR to detect single-nucleotide polymorphisms, we
were able to distinguish two different blaSHV genes in a single isolate. This may prove to be a useful technique
in surveys of beta-lactamase production in contemporary clinical isolates.
It has long been known that extended-spectrum -lactamase
(ESBL)-producing bacteria cause serious clinical problems (2,
9). ESBL production has become frequent not only in Esche-
richia coli and Klebsiella pneumoniae but also in other species
of Enterobacteriaceae (10). Currently, ESBL-producing organ-
isms frequently produce multiple -lactamases (3, 7, 16). This
can include the production of ESBLs and non-ESBLs of dif-
ferent types, synthesis of multiple ESBLs of the same type (for
example, production of multiple TEM-type ESBLs by the same
isolate) (3), or elaboration of chromosomally encoded SHV-1
and an SHV-type ESBL (6).
There are a number of ways in which different -lactamase
types can be differentiated within a single isolate (8). Analytical
isoelectric focusing can provide a clue to the presence and
isoelectric points (pIs) of multiple -lactamases produced by a
single isolate. However, many different -lactamases share
common isoelectric points, so this method lacks the ability to
identify the -lactamase type. We have previously performed
surveys in which blaSHV, blaTEM, or blaCTX-M genes were am-
plified, and the primary PCR product was identified by se-
quencing (16). Such a procedure is easily performed but may
not identify multiple -lactamases of the same type: genes
existing in a lower copy number may be less likely to be de-
tected than those which predominate. The definitive method
for detecting multiple -lactamases of the same type is exten-
sive cloning and sequencing of the bla genes.
Herein, we report an Enterobacter cloacae isolate which si-
multaneously produced two different SHV-type ESBLs. We
describe a real-time PCR method for detecting single-nucle-
otide polymorphisms (SNPs) that uses fluorescently labeled
oligonucleotide hybridization probes (20). We demonstrate a
rapid, sensitive, and specific method that can detect mutations
of the blaSHV gene in a single reaction. As a result of this
analysis, we identified a novel SHV variant, SHV-30, in a
complex -lactamase background.
MATERIALS AND METHODS
Bacterial isolates. An E. cloacae isolate (designated “ES24”) was detected in
2003 in blood cultures from a solid-organ transplant recipient in Pittsburgh. The
following isolates were used as controls: K. pneumoniae ATCC 700603 (produc-
ing SHV-18) (19), a KPC-1-producing K. pneumoniae isolate (producing SHV-
29) (23), E. coli EP-MAX10B, and a well-characterized clinical isolate of E.
cloacae producing an AmpC type -lactamase. Additionally, well-characterized
clinical isolates of E. cloacae producing SHV-5, SHV-7, and SHV-14 were also
used (Table 1).
Antibiotic susceptibility. The MICs of various antibiotics were determined
using Etest strips (AB Biodisk, Solna, Sweden). Susceptibility tests were per-
formed according to the manufacturer’s instructions. The following Etest strips
were used: aztreonam, cefotaxime, cefotaxime plus clavulanic acid, ceftazidime,
ceftazidime plus clavulanic acid, cefepime, cefepime plus clavulanic acid, cefox-
itin, and ciprofloxacin. E. coli ATCC 25922 was used as the reference isolate for
antimicrobial susceptibility testing. All susceptibility results were interpreted
using the breakpoints of the Clinical and Laboratory Standards Institute (for-
merly NCCLS), current as of 1 January 2005 (15).
Plasmid isolation and transformation. Plasmid DNA from the E. cloacae
ES24 isolate was extracted and purified using the protocol and reagents of a
commercial kit (Quantum Prep; Bio-Rad, Inc., Hercules, CA) The plasmids were
analyzed by electrophoresis on a 0.8% (wt/vol) agarose gel and visualized by
ethidium bromide staining under UV light.  HindIII (Promega, Madison, WI)
was used as a molecular weight marker. The plasmid DNA of the E. cloacae ES24
isolate was used to transform electrocompetent E. coli EP-MAX10B (Bio-Rad,
Inc.). Transformants were selected on Luria-Bertani agar (Beckton Dickinson,
Sparks, MD) containing 0.5 g/ml cefotaxime (Sigma, St. Louis, MO).
Isoelectric focusing. Analytical isoelectric focusing (IEF) was performed to
determine the pIs of -lactamases extracted from the E. cloacae ES24 isolate and
the plasmid-transformed E. coli EP-MAX10B isolate (17). Electrophoresis was
performed on precast polyacrylamide gels, pH 3 to pH 10 (Bio-Rad Inc.). Iso-
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electric points were determined by placing filter paper soaked in nitrocefin (500
g/ml; Becton Dickinson) on top of the focused gel (17).
PCR and cloning. A single colony of each test isolate was resuspended in 400
l water and boiled for 15 min. The resulting supernatant was used as the
bacterial DNA template for PCR amplification. The primers are shown in Table
2. Reaction mixtures (30 l) contained 50 mM KCl, 1.5 mM MgCl2, 0.5 M of
each primer, 1.5 mM of each deoxynucleotide triphosphate (Sigma), 1 U of
RedTaq polymerase (Sigma), and 2 l of the bacterial DNA template. Initially,
direct sequencing of the products was performed.
Next, the amplified blaSHV PCR products were cloned into a pCR-XL-TOPO
(TOPO XL PCR cloning kit; Invitrogen, Carlsbad, CA) vector that encodes a
kanamycin resistance determinant. The amplified product’s nucleotide sequences
were determined using the ABI 3700 and ABI 3100 genetic analyzers according to
the manufacturer’s instructions. Sequence analysis was performed using the Laser-
gene DNAStar sequencing analysis software (DNAStar, Madison, WI).
Real-time PCR SNP genotyping. To detect the single-nucleotide polymor-
phisms in blaSHV, we used the 5 nuclease assay developed by Sevall (20). We
designed fluorogenic probes consisting of oligonucleotides that possess a re-
porter dye (6-carboxy-2,4,4,5,7,7-hexachlorofluorescein [HEX] or 6-carboxy-
fluorescein [FAM]) and a quencher dye (6-carboxytetramethylrhodamine
[TAMRA]) at each end. The probe adopts a hairpin structure while free in
solution. The close proximity of the reporter and the quencher in this hairpin
suppresses reporter fluorescence (fluorescence resonance transfer [FRET]).
During PCR, the dual-labeled probe annealed to the target of interest (blaSHV)
between the forward and reverse primer sites. During extension, the probe was
cleaved by the 5 nuclease activity of the Taq polymerase. This separated the
reporter dye from the quencher dye, generating an increase in the reporter dye’s
fluorescence intensity (FRET does not occur). Thus, by using two probes con-
taining only a single nucleotide difference combined with two different reporter
dyes, single-nucleotide polymorphisms were detected.
Real-time PCR allelic discrimination assays (SNP genotyping) were designed
using Primer Express software (Applied Biosystems, Foster City, CA). Primer
and probe combinations designed using Primer Express are listed in Table 2.
Genotyping was performed in 50-l reaction mixtures that contained 5 l of
genomic DNA, 900 nM of each primer, 200 nM of each probe, and 25 l of
Taqman Universal PCR Master Mix (contains PCR buffer, passive reference dye
ROX [carboxy-X-rhodamine], deoxynucleotides, uridine, uracil-N-glycosylase,
and AmpliTaq Gold DNA polymerase; Perkin-Elmer Applied Biosystems). Am-
plification was performed using an ABI 7000 real-time thermal cycler. Cycling
conditions were 2 min at 50°C, 10 min at 95°C, 40 cycles of 95°C for 15 s, and
60°C for 1 min. Real-time fluorescence detection was performed during the 60°C
annealing/extension step of each cycle. ABI allelic discrimination software was
used to plot and automatically call genotypes based on a two-parameter plot
using fluorescence intensities of FAM and HEX at 40 cycles. This software uses
autoscaling for the allelic discrimination plot.
Nucleotide sequence accession number. The DNA sequence and deduced
amino acid sequence of SHV-30 has been deposited in GenBank and assigned
accession number AY661885.
RESULTS
Phenotypic characterization of E. cloacae ES24. We isolated
six plasmids from the E. cloacae ES24 isolate. The plasmids had
the following estimated sizes: 9.4, 3.0, 2.5, 2.3, 2.0, and0.8 kb. In
an attempt to isolate plasmids harboring genes encoding -lacta-
mases, transformation experiments were performed. It was only
possible to transform the largest plasmid (9.4 kb) into E. coli
EP-MAX10B. The antibiotic susceptibilities of both the E. cloa-
cae ES24 and the plasmid-transformed E. coli EP-MAX10B iso-
lates are shown in Table 3. ES24 was resistant to ceftazidime,
aztreonam, and cefoxitin but was intermediate to cefotaxime and
cefepime. The cefepime MIC decreased in the presence of cla-
vulanic acid. The MICs of the plasmid-transformed E. coli EP-
MAX10B isolate were much lower than those of E. cloacae ES24
(Table 3), with MICs for all tested antibiotics being in the sus-
ceptible range.
In order to characterize the -lactamases from E. cloacae
ES24 and the plasmid-transformed E. coli EP-MAX10B iso-
late, isoelectric focusing was performed. Four different -lac-
TABLE 1. -lactamase production of the isolates used in this study
Isolate (no.) -Lactamase Reference
K. pneumoniae ATCC 700603 SHV-18 19
KPC-1 K. pneumoniae SHV-29, KPC-1, TEM-1 23
E. coli EP-MAX10B
E. cloacae ES24 AmpC, SHV-7, SHV-30,
TEM-1
This study
Plasmid-transformed E. coli
EP-MAX10B
SHV-30 This study
E. cloacae clinical isolate (1) AmpC This study
E. cloacae clinical isolate (2) AmpC, SHV-5 This study
E. cloacae clinical isolate (5) AmpC, SHV-7 This study
E. cloacae clinical isolate (1) AmpC, SHV-14 This study
TABLE 2. Primers and probes used in this study
PCR Primers, probes Sequence Reference
TEM Forward primer 5 ATG AGT ATT CAA CAT TTC CG TG 3 7
Reverse primer 5 TTA CCA ATG CTT AAT CAG TGA G 3
SHV Forward primer 5 ATT TGT CGC TTC TTT ACT CGC 3 22
Reverse primer 5 TTT ATG GCG TTA CCT TTG ACC 3
RTaSNP Forward primerb 5 TTG TTA TTC GGG CCA AGC 3 This study
Reverse primerb 5 TGG TTT ATC GCC GAT AAC 3 This study
Probe 1b 5 FAM-ACC CCG TTC GCT AGC TCC GG-TAMRA 3 This study
Probe 2b 5 HEX-ACC CCG TTT GCT AGC TCC GG-TAMRA 3 This study
a RT, real-time.
b The primers and probes were designed for the reverse complementary DNA strand. Underlined letters indicate bases complementary to the polymorphic locus.
TABLE 3. MIC values of the E. cloacae ES24 isolate and the
plasmid-transformed E. coli EP-MAX10B by Etest
Antibiotic
MIC (g/ml) for:
E. cloacae ES24 Plasmid-transformedE. coli EP-MAX10B
Ceftazidime 256 1.5
Ceftazidime/clavulanic acid 4 0.38
Cefotaxime 12 1
Cefotaxime/clavulanic acid 1 0.094
Aztreonam 256 0.38
Cefoxitin 256 4
Cefepime 16 0.38
Cefepime/clavulanic acid 1.5 0.064
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tamases with pI values of 5.4, 6.7, 7.6, and 9 were identified
in the E. cloacae ES24 isolate. The plasmid-transformed E. coli
EP-MAX10B isolate produced only one -lactamase (with a pI
value of 6.7) (Fig. 1).
PCR amplification and sequencing analysis. PCR amplifi-
cation of bla genes in E. cloacae ES24 identified both blaTEM
and blaSHV. The blaTEM was identified as blaTEM-1. Sequence
analysis of the blaSHV PCR product revealed three nucleotide
substitutions in the E. cloacae ES24 isolate that resulted in
three amino acid changes. At Ambler position 8, Ile changed to
Phe; at position 43, Arg changed to Ser; and at position 238,
Gly changed to Ser. Further sequence analysis in E. cloacae
ES24 revealed two different codons at Ambler position 240,
GAA (Glu) and AAA (Lys), i.e., two peaks were seen (Fig. 2).
In order to confirm that the E. cloacae ES24 isolate was
producing different SHV-enzymes, the blaSHV PCR product of E.
cloacae ES24 isolate was cloned into the TOPO vector. The
cloned isolates carried either the blaSHV-7 gene (position 8, Ile to
Phe; position 43, Arg to Ser; position 238, Gly to Ser; and position
240, Glu to Lys) or the novel blaSHV-30 gene (position 8, Ile to
Phe; position 43, Arg to Ser; and position 238, Gly to Ser) (12).
The plasmid-transformed E. coli EP-MAX10B isolate was
found to be negative for blaTEM by PCR amplification, but it
was found to be positive for blaSHV. The sequence analysis
showed that the plasmid-transformed E. coli EP-MAX10B iso-
late carried only the novel blaSHV-30 gene. This finding was
further confirmed by IEF (Fig. 1).
Real-time PCR SNP genotyping. Real-time PCR SNP was
performed on the E. cloacae ES24 isolate (SHV-7 and SHV-
30) and plasmid-transformed E. coli EP-MAX10B (SHV-30)
as well as the following control isolates: K. pneumoniae ATCC
700603 (SHV-18), KPC-1-producing K. pneumoniae isolate
(SHV-29), an E. coli EP-MAX10B isolate, AmpC -lacta-
mase–producing clinical E. cloacae isolate, and ESBL (SHV-5,
SHV-7, and SHV-14)-producing and AmpC -lactamase–pro-
ducing clinical E. cloacae isolates (Table 1).
In our study, probes were designed to identify mutations
affecting amino acid position 240 alleles GAA (Glu) and AAA
(Lys) (1). Table 4 lists the results of the isolates tested and a
comparison of their nucleotide sequences at the positions of
probes. If the probes hybridized, the increase in fluorescence
signal of one dye over the other indicated homozygosity for that
PCR allele (FAM fluorescence for the G allele, and HEX fluo-
rescence for the A allele). An increase in both signals indicated
heterozygosity. The amplification fluorescence intensities are
compared in a graphical form (Fig. 3). Clusters of points on the
graph correspond to the homozygous G genotype, the homozy-
gous A genotype, the heterozygous GA genotype, or to a geno-
type with no amplification.
The E. cloacae ES24 isolate showed substantial increases in
both FAM and HEX dye fluorescence (Fig. 3). An increase in
both signals indicates heterozygosity for G and A alleles at
nucleotide position 703.
The plasmid-transformed E. coli EP-MAX10B (SHV-30-
producing) isolate and the SHV-14-producing clinical E. cloa-
cae isolates showed increased FAM fluorescence and un-
changed HEX fluorescence, indicating homozygosity for the
FAM-specific G allele. Only the G at the 703 nucleotide posi-
tion was present (Fig. 3). However, the SHV-14-producing E.
cloacae isolate contained one nucleotide difference at position
700 relative to the probe (Table 4).
The two SHV-5-producing and the five SHV-7-producing
clinical E. cloacae isolates showed increases in only HEX dye
fluorescence, indicating the specific A allele at nucleotide po-
sition 703 (Fig. 3).
The SHV-18-producing K. pneumoniae ATCC 700603 isolate
and the SHV-29-producing KPC-1 isolate showed no change in
the fluorescence intensity for either FAM or HEX (Fig. 3). Based
on their sequencing results, the SHV-18-producing K. pneu-
moniaeATCC 700603 isolate had an A nucleotide at position 703,
and the SHV-29-producing KPC-1 isolate had a G nucleotide at
position 703; despite this, there was no increase in fluorescence
signal for the HEX-specific A allele and the FAM-specific G
allele. The reason is that both isolates have two differences at
nucleotide positions 700 and 701 relative to the probes (Table 4),
resulting in a lack of binding of the specific probe.
The nontransformed E. coli EP-MAX10B isolate and the chro-
mosomal AmpC -lactamase–producing E. cloacae isolate also
FIG. 1. Isoelectric focusing of strain ES24 and the SHV-30-produc-
ing, plasmid-transformed E. coli EP-MAX10B isolate. Lane 1, IEF
standard; lane 2, strain ES24; lane 3, the SHV-30-producing, plasmid-
transformed E. coli EP-MAX10B isolate.
FIG. 2. The sequencing result of the ES24 isolate from position 692
to position 711. N indicates two different peaks (G and A).
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showed no change in fluorescence intensity for either FAM or
HEX (Fig. 3) because they did not contain the blaSHV gene.
DISCUSSION
Enterobacter spp. produce a chromosomally encoded AmpC
-lactamase. Enterobacter isolates have also been reported to
produce ESBLs of TEM and SHV types. Of these, SHV-7 has
been recently reported from E. cloacae isolates in Philadelphia
(11). SHV-7 -lactamase was first identified in an E. coli isolate
in 1995 in New York (4) and has also been produced in K.
pneumoniae isolates (21).
Our E. cloacae ES24 isolate produced AmpC, TEM-1, and
SHV-7 -lactamases and a novel -lactamase, SHV-30, with a
pI of 6.7. This is the first isolation of SHV-30 from an Enter-
obacter isolate and the first report of an E. cloacae isolate
producing two different SHV enzymes. The amino acid se-
quence of SHV-30 differed from the amino acid sequence of
SHV-1 by three amino acid substitutions: isoleucine for phe-
nylalanine at position 8, arginine for serine at position 43, and
glycine for serine at position 238. An investigation of the effect
of these mutations on the active site of the enzyme and on
antibiotic hydrolysis is under further investigation.
Methods that can be used to rapidly and reliably character-
ize -lactamases and the genes that encode them are still being
sought. To identify two different blaSHV genes within a single
bacterial isolate is not simple. To assist with this, a combina-
tion of isoelectric focusing and restriction fragment length
polymorphism (RFLP) analysis of SHV-specific PCR products
FIG. 3. Allelic discrimination. }, SHV-30-producing, plasmid-transformed E. coli EP-MAX10B isolate and SHV-14-producing E. cloacae
isolate; Œ, E. cloacae ES24; ●, two SHV-5-producing and five SHV-7 producing E. cloacae isolates; –, SHV-18-producing K. pneumoniae ATCC
700603, SHV-29-producing KPC-1 isolate, E. coli EP-MAX10B, and chromosomal AmpC -lactamase–producing E. cloacae isolate; ■, water.
TABLE 4. Comparison of the nucleotide sequence (692 to 711) of the SHV positive isolates and the allelic discrimination result
blaSHV gene(s)
No. of
isolate Origin Sequencing result
a Allelic discrimination result
SHV-30 1 Plasmid-transformed E. coli EP-
MAX10B
CC GGA GCT AGC GAA CGG GGT Allele G
SHV-14 1 Clinical E. cloacae isolate CC GGA GCT GGC GAA CGG GGT Allele G
SHV-7, SHV-30 1 E. cloacae ES24 CC GGA GCT AGC KAA CGGGGTb Allele G A
SHV-5 2 Clinical E. cloacae isolate CC GGA GCT AGC AAA CGG GGT Allele A
SHV-7 5 Clinical E. cloacae isolate CC GGA GCT AGC AAA CGG GGT Allele A
SHV-18 1 K. pneumoniae ATCC 700603 CC GGA GCT GCC AAA CGG GGT Indeterminate
SHV-29 1 KPC-1 producing K. pneumoniae CC GGA GCT GCC GAA CGG GGT Indeterminate
a The underlined residues in the sequence differ from the probes. Boldface type indicates the polymorphic locus.
b K indicates G and A together.
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has been developed (8). As noted previously, determination of
the pI of the enzyme is insufficient to identify SHV-derived
-lactamases due to the frequent similarity of pI values. The
PCR-RFLP technique is a simple and rapid alternative, but it
cannot identify all known mutations, such as those affecting
amino acids at positions 8, 238, or 240. PCR single-strand
conformational polymorphism analysis was developed to char-
acterize -lactamases in the SHV family (13). PCR single-
strand conformational polymorphism analysis has also been
used to differentiate two different blaSHV gene types within a
single bacterial isolate (14, 24). Restriction site insertion-PCR
has been used to detect mutations of blaSHV genes that cannot
be identified by PCR-RFLP. This technique uses primers with
one to three base mismatches near the 3 end which modulate
target restriction sites (5). All of these techniques, however,
rely on the high specificity of restriction endonucleases to iden-
tify the restriction sites.
Real-time PCR and melting-curve analysis have been previ-
ously used for rapid detection of the blaSHV ESBLs (18). We
have used a rapid method based on FRET real-time PCR to
identify two different blaSHV genes in a single E. cloacae iso-
late. Real-time allelic discrimination is a fluorescence detec-
tion system that collects fluorescence measurements during the
amplification. The DNA assay with amplification and detection
in a single step allows the analysis of the amplification product
without extensive postamplification processing. A mismatch
between probe and target greatly reduces the efficiency of
probe hybridization and its subsequent hydrolysis. In our case,
if there were two additional nucleotide mismatches, the probes
were unable to hybridize.
With this method, probes also can be designed to identify
every target, even those that do not generate unique restriction
endonuclease sites. With this method, more than two alleles
could potentially be distinguished. The further advantage of
this method is that it could be used for genes encoding other
types of -lactamases, such as blaCTX-M or blaTEM.
In summary, the real-time PCR SNP assay proved useful in
a situation where amplification from genome extracts, with
sequencing of the primary PCR product, suggested that two
-lactamases were present. We found the technique to be highly
reproducible, and it could be performed without postamplifica-
tion steps. The present assay was designed to conform to standard
thermocycling conditions, thus allowing several SNPs to be iden-
tified simultaneously. This approach may be extremely useful
when applied to large population survey studies that attempt to
define the molecular epidemiology of -lactamase genes.
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